Replimune announced its intention to resubmit its melanoma treatment to the FDA after experiencing two rejections under the previous leadership, which included former Commissioner Marty Makary.
The company had previously accused the FDA of unjustly blocking what many doctors consider a promising treatment option for skin cancer, while the FDA maintained that Replimune did not adhere to its clinical trial guidelines.
The situation highlighted concerns within the pharmaceutical industry regarding inconsistent messaging from the FDA, which some drugmakers felt could hinder the development of new therapies. Following a constructive dialogue with the FDA, Replimune expressed optimism about the resubmission, stating that the agency would prioritize the review of the application.
This news has resonated positively with investors, as evidenced by a 70% spike in Replimune's shares during premarket trading, raising the company's market value to $386 million as of the previous day's close